Publish time: 2023-04-10 00:00:00
12A-1110630
US Provisional Application
Inflammation is associated with worse outcomes in many diseases. We constructed several monoclonal antibodies (mAbs) against a specific human protein (XA). Our results demonstrate that XA mAbs modulate macrophage phenotype toward M2-like phenotypes, reduce inflammation and protect against inflammatory related damage in three mouse models. 1). Two-hours-delayed intravenous injection, XA mAbs reduced brain injury and improved neurological function in an hemorrhagic stroke mouse model. 2). XA mAbs (IP injected) reduced imiquimod-induced skin thickness, inflammatory cytokine (TNF-α, IL-17A and IL-23) expression in a psoriasis mouse model. 3). XA mAbs (IP) reduced LPS-induced microglia and astrocyte activation and IL-6 expression in hippocampus, and reduce brain atrophy in a sepsis-associated encephalopathy (SAE) mouse model. Thus, XA mAb treatment may be a novel therapeutic approach against brain, skin and systemic inflammatory diseases.
- Modulate monocytes/macrophages/microglia to M2 to suppress inflammation and enhance repairing.
- Reduce systemic and brain inflammation
- Can be IP or IV injected, easy to delivery.
- Less mAb required (1/10~ 1/50 of regular dosage)
- Affect Fc receptor expressing cells only but not other normal cells.
- Several mAbs available with sequences determined.
- Treatment for inflammation-related diseases.
- Brain disease, hemorrhagic stroke, brain inflammation.
- Psoriasis, autoimmune-related.
- Systemic and regional (brain disease)
Song-Kun Shyue
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Monoclonal Antibody for Use in Treating Inflammation-related Diseases Modulating Macrophages to M2-like Phenotype to Reduces Inflammation and Injury in Hemorrhagic Stroke, Psoriasis and Sepsis-induced Brain Inflammation (SAE)